Navidea Biopharmaceuticals (NAVB) Announces Eleven Scientific Presentations Of Results From Lymphoseek® And Manocept™ Studies At The Society Of Nuclear Medicine And Molecular Imaging (SNMMI) Annual Meeting
5/20/2014 6:56:15 AM
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data and results from its Lymphoseek® (technetium Tc 99m tilmanocept) Injection studies in breast cancer, melanoma or head and neck cancer and its Manocept™ studies in Rheumatoid Arthritis and Kaposi Sarcoma are being presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting from June 7-14, 2014 in St. Louis, MO. Details of the eleven presentations by Navidea and its collaborators are listed below.
Help employers find you! Check out all the jobs and post your resume.
comments powered by